ДИАГНОСТИЧЕСКАЯ ЭФФЕКТИВНОСТЬ, БЕЗОПАСНОСТЬ И БИОЭКВИВАЛЕНТНОСТЬ ПРИМЕНЕНИЯ ГАДОБУТРОЛА У ДЕТЕЙ ДО 2 ЛЕТ ПО СРАВНЕНИЮ С БОЛЕЕ СТАРШИМИ ДЕТЬМИ И ВЗРОСЛЫМИ

Приведены сведения о безопасности, диагностической эффективности и биоэквивалентности применения гадобутрола у новорожденных и младенцев по сравнению с детьми более старшего возраста и взрослыми пациентами. Профиль фармакокинетики гадобутрола у детей в возрасте младше 2 лет, включая доношенных новорожденных, аналогичен тому, что имеет место у детей более старшего возраста и взрослых. При стандартной дозе 0,1 ммоль/кг массы тела гадобутрол имеет благоприятный профиль безопасности и хорошо переносится детьми любого возраста и взрослыми. Получены доказательства возможности экстраполяции применения гадобутрола у детей младше 2 лет, включая доношенных новорожденных, для эффективной диагностики нарушений гематоэнцефалического барьера и патологических изменений сердечно-сосудистой системы и очаговых заболеваний других внутренних органов.

обзор, магнитно-резонансная томография, контрастное усиление, гадобутрол, новорожденные, младенцы, фармакокинетика, макроциклический препарат

1. American College of Radiology. Manual on contrast media version 8. American College of Radiology website; 2012. Available at: http://www.acr.org/Quality-Safety/Resources/Contrast-Manual (accessed 27 May 2015).

2. Nephrogenic systemic fibrosis. American College of Radiology. Manual on contrast media – version 7; 2010.

3. Алиханов А.А., Шимановский Н.Л. Применение магнитно-резонансных контрастных средств в детской практике. Лучевая диагностика и терапия. 2016; 1: 82–94. [Alikhanov A.A., Shimanovskiy N.L. The use of magnetic resonance contrast media in pediatric practice. Luchevaya Diagnostika i Terapiya (Diagnostic Radiology and Radiotherapy, Russian journal). 2016; 1: 82–94 (in Russ.).]

4. Bhargava R., Noga M. Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years – a single-center, observational study. Magn. Reson. Insights. 2013; 6: 1–12.

5. European Medicines Agency (EMEA), Committee for medicinal products for human use (CHMP). Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. London, United Kingdom: EMEA; 2006.

6. US Food and Drug Administration. FDA drug safety communication: new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. U.S. Department of Health and Human Services. Available at: h t t p : / / w w w. f d a . g o v / D r u g s /DrugSafety/ucm223966 (accessed 29 September 2014).

7. EMEA. Committee for Proprietary Medicinal Products (CPMP).Discussion paper on the impact of renal immaturity when investigating medicinal products intended for paediatric use. London, United Kingdom: EMEA; 2004.

8. Thomsen H.S., Morcos S.K., Almén T. et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur. Radiol. 2013; 23: 307–18.

9. Bhargava R., Hahn G., Hirsch W. et al. Contrast-enhanced magnetic resonance imaging in pediatric patients: review and recommendations for current practice. Magn. Reson. Insights. 2013; 6: 95–111.

10. Nardone B., Saddleton E., Laumann A.E. et al. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr. Radiol. 2014; 44: 173–80.

11. Heilbron D.C., Holliday M.A., al-Dahwi A. et al. Expressing glomerular filtration rate in children. Pediatr. Nephrol. 1991; 5: 5–11.

12. Hogg R.J., Furth S., Lemley K.V. et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003; 111 (6 Pt 1): 1416–21.

13. Anzalone N., Scarabino T., Venturi C. et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0 M) and gadoterate meglumine (0.5 M) at 0.1 mmol Gd/kg body weightin a clinical setting. Eur. J. Radiol. 2013; 82: 139–45.

14. Hadizadeh D.R., Von Falkenhausen M., Kukuk G.M. et al. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate. Am. J. Roentgenol. 2010; 194: 821–9.

15. Hammerstingl R., Adam G., Ayuso J.R. et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase III trial. Invest. Radiol. 2009; 44: 168–76.

16. Huppertz A., Rohrer M. Gadobutrol, a highly concentrated MRimaging contrast agent: its physicochemical characteristics and the basis for its use in contrastenhanced MR angiography and perfusion imaging. Eur. Radiol. 2004; 14 (Suppl 5): M12–M18.

17. Tombach B., Bohndorf K., Brodtrager W. et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial. Eur. Radiol. 2008; 18: 2610–9.

18. Tombach B., Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur. Radiol. 2002; 12: 1550–6.

19. Frenzel T., Lengsfeld P., Schirmer H. et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest. Radiol. 2008; 43: 817–28.

20. Forsting M., Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol – a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur. J. Radiol. 2010; 74: e186–e192.

21. European Medicines Agency (EMA). Assessment report for gadoliniumcontaining contrast agents (Procedure No. EMEA/H/A-31/1097). 1 July 2010 EMA/74064 0/2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500099538.pdf

22. Food and Drug Administration (FDA). FDA Drug Safety Communication: new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm2239 66.htm (accessed 27 May 2015).

23. Staks T., Schuhmann-Giampieri G., Frenzel T. et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest. Radiol. 1994; 29: 709–15.

24. Chooi W.K., Woodhouse N., Coley S.C. et al. Pediatric head and neck lesions: assessment of vascularity by MR digital subtraction angiography. Am. J. Neuroradiol. 2004; 25: 1251–5.

25. Martí-Bonmatí L., Vega T., Benito C. et al. Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study. Invest. Radiol. 2000; 35: 141–7.

26. Hahn G., Sorge I., Gruhn B. et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest. Radiol. 2009; 44: 776–83.

27. Scott L.J. Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin. Drug. Investig. 2013; 33: 303–14.

28. Voth M., Rosenberg M., Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest. Radiol. 2011; 46: 663–71.

29. Kunze C., Mentzel H.J., Krishnamurthy R., Fleck R., Stenzel M., Bhargava R. et al. Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Invest. Radiol. 2016; 51 (1): 50–7.

30. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for industry: population pharmacokinetics. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, CDER, and CBER; 1999.

31. Reif S., Schultze-Mosgau M., Sutter G. From adults to children: simulation-based choice of an appropriate sparse-sampling schedule. Paediatr. Drugs. 2012; 14: 189–200.

32. Gutierrez J.E., Rosenberg M., Duhaney M. et al. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system. J. Magn. Reson. Imaging. 2015; 41: 788–96.

33. Шимановский Н.Л. Контрастные средства: Руководство по рациональному применению. М.: ГЭОТАР-Медиа; 2009. [Shimanovskiy N.L. Contrast Media: Guide of rational use. Moscow: GEOTARMedia; 2009 (in Russ.).]

34. Алиханов А.А., Шимановский Н.Л. Преимущества применения одномолярного гадолинийсодержащего магнитно-резонансного контрастного средства по сравнению с полумолярными препаратами при диагностике рассеянного склероза. Медицинская визуализация. 2008; 5: 73–80. [Alikhanov A.A., Shimanovskiy N.L. The advantages of using of 1-molar gadolinium magnetic resonance contrast media compared to 0,5-molar agents in the diagnosis of multiple sclerosis. Meditsinskaya Vizualizatsiya (Medical Visualization, Russian journal). 2008; 5: 73–80 (in Russ.).]

35. Coté C.J., Wilson S. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics. 2006; 118 (6): 2587–602.

36. Schulte-Uentrop L., Goepfert M.S. Anaesthesia or sedation for MRI in children. Curr. Opin. Anaesthesiol. 2010; 23 (4): 513–7.

37. Wachtel R.E., Dexter F., Dow A.J. Growth rates in pediatric diagnostic imaging and sedation. Anesth. Analg. 2009; 108 (5): 1616–21.

38. Heng V.C., Bajard A., Thiesse P. Deep sedation in pediatric imaging: efficacy and safety of intravenous chlorpromazine. Pediatr. Radiol. 2012; 42 (5): 552–61.